The pharmacokinetics of numerous drugs, including many that are commonly<unk> ministered to individuals with heart disease, are affected by<unk> . Particularly, doses of digoxin should be halved in individuals taking<unk> .<unk>  may also interact with sotalol.<unk>  potentiates the action of warfarin by inhibiting the clearance of both (S) and (R) warfarin. Individuals taking both of these medications should have their warfarin doses<unk> justed based on their dosing of<unk> , and have their anticoagulation status (measured as prothrombin time (PT) and international normalized ratio (INR)) measured more frequently. Dose reduction of warfarin is as follows: 40% reduction if<unk>  dose is 400 mg daily, 35% reduction if<unk>  dose is 300 mg daily, 30% reduction if<unk>  dose is 200 mg daily, and 25% reduction if<unk>  dose is 100 mg daily. The effect of<unk>  on the warfarin concentrations can be as early as a few days after initiation of treatment; however, the interaction may not peak for up to seven weeks.<unk>  inhibits the action of the cytochrome P450 isozyme family. This reduces the clearance of many drugs, including the following: * Ciclosporin * Digoxin * Flecainide * Procainamide * Quinidine * Sildenafil * Simvastatin * Theophylline * Warfarin In 2015, Gilead Sciences warned health care providers about people that began taking the hepatitis C drugs ledipasvir/sofosbuvir or sofosbuvir along with<unk> , who developed abnormally slow heartbeats or died of cardiac arrest.
Amiodarone
Ibutilide
Colestilan
Flecainide
Verapamil
Acecainide
Sotalol
Dofetilide